MedTrace Logo

Double Blind Trial in Children With Autism Spectrum Disorder

NCT06058962 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2023-11-13

No results posted yet for this study

Summary

This study investigated the safe and efficacious use of suramin as a novel treatment for ASD by testing two suramin doses vs placebo

Conditions

Interventions

DRUG

Suramin Sodium

Suramin sodium is a sodium salt form of suramin, an antitrypanosomal compound.

Sponsors & Collaborators

  • Paxmedica

    lead INDUSTRY

Principal Investigators

  • jennifer L bonfrisco · Paxmedica

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2021-01-15
Completion
2021-03-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06058962 on ClinicalTrials.gov